Methods for collecting and reporting to the Agency data on the use of antimicrobial medicinal products
Article 13
1. In order to facilitate the collection of standardised and harmonised data on the use of the antimicrobial medicinal products referred to in Articles 3 and 4, Member States shall collect those data: (a) from the following data providers, as appropriate: veterinarians, retailers, pharmacies, feed mills and end-users, including farmers or breeders; (b) based on the following data sources, as appropriate: health records, treatment logbooks, delivery notes, invoices from farms, prescriptions, pharmacy records or veterinary practice records; (c) using the systems for the collection of data on use referred to in Article 14. 2. Member States shall report their data on the use of the relevant veterinary antimicrobial medicinal products and antimicrobial medicinal products for human use, which may exceptionally be used in animals, for each product presentation, and for relevant animal species, categories or stages described in Article 15. They shall ensure that the data cover all uses of the relevant antimicrobial medicinal products during the preceding calendar year within their respective Member State territories, in line with Article 6(e). The first report shall be sent to the Agency by 30 September 2024 and shall cover the data of antimicrobial medicinal products used during the preceding calendar year for relevant animal species, categories or stages. The following reports after the first report shall be sent to the Agency by 30 June of each year and shall cover the data of antimicrobial medicinal products used during the preceding calendar year for relevant animal species, categories or stages. 3. Member States shall report their data on the use of the relevant antimicrobials via the web interface, using the protocols and templates made available to this end by the Agency and taking account of other relevant guidance documents produced by the Agency. 4. Member States shall also report the following information to the Agency, via their national contact points and data managers and using the web interface: (a) the type of data providers and data sources from which they collected their data on use, along with a short description of the main characteristics of their national systems for collection of data on use of antimicrobial medicinal products in animals; (b) the coverage and accuracy of their data on use, together with measures taken to avoid double reporting; (c) any initiatives led within the country or any relevant specific factors which may explain the results observed at national level, including possible pattern changes and trends; (d) a brief description of their national policy framework or main initiatives in place to fight antimicrobial resistance and reduce any use of antimicrobials in animals that is neither prudent nor responsible. 5. Member States shall provide the information described in paragraph 4 for the first data report by 30 September 2024 and update it subsequently in the following reporting periods, as applicable.